Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Amgen buys BioVex for up to $1bn

Executive Summary

Amgen Inc. has agreed to acquire privately held immunotherapeutics company BioVex Inc. for up to $1bn, with $425mm paid in cash up front, plus the opportunity for up to $575mm in regulatory and sales milestones. BioVex will become a wholly owned subsidiary of Amgen.
Deal Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
    • Vaccines
Deal Status
  • Final
Deal Type
  • Acquisition
    • Includes Earnout
    • Intra-Biotech Deal
    • Full Acquisition
    • Acquisition of Private Biotech
    • Includes Contract
    • Payment Includes Cash

Related Companies

Advertisement
UsernamePublicRestriction

Register